NCT02138422 2021-03-01
A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer
Janssen Research & Development, LLC
Phase 3 Completed
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Cedars-Sinai Medical Center